AREV Life Sciences Global Corp.
AREVF
$0.01
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -96.35% | -84.51% | -82.36% | -81.33% | 10.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.35% | -84.51% | -82.36% | -81.33% | 10.76% |
| Cost of Revenue | 18.55% | 18.55% | -73.98% | -73.98% | -71.88% |
| Gross Profit | -107.08% | -93.90% | -86.30% | -84.16% | 52.70% |
| SG&A Expenses | -95.55% | -83.65% | -44.74% | -25.14% | 10.28% |
| Depreciation & Amortization | -49.86% | -38.45% | -26.80% | -17.28% | -11.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -89.84% | -78.08% | -41.84% | -25.19% | 7.19% |
| Operating Income | 89.13% | 77.36% | 36.25% | 16.50% | -6.81% |
| Income Before Tax | 77.59% | 56.57% | -14.90% | -43.58% | 49.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 77.59% | 56.57% | -14.90% | -43.58% | 49.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 77.59% | 56.57% | -14.90% | -43.58% | 49.49% |
| EBIT | 89.13% | 77.36% | 36.25% | 16.50% | -6.81% |
| EBITDA | 91.80% | 80.26% | 36.92% | 16.35% | -8.83% |
| EPS Basic | -124.34% | -149.77% | -245.08% | -393.89% | 131.70% |
| Normalized Basic EPS | 91.49% | 83.61% | 59.95% | 49.69% | -19.15% |
| EPS Diluted | -124.34% | -149.77% | -245.08% | -393.89% | 131.70% |
| Normalized Diluted EPS | 91.49% | 83.61% | 59.95% | 49.69% | -19.15% |
| Average Basic Shares Outstanding | 33.19% | 39.45% | 45.89% | 52.90% | 5.27% |
| Average Diluted Shares Outstanding | 33.19% | 39.45% | 45.89% | 52.90% | 5.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |